| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 11.577 | 16.722 | 24.038 | 31.510 | 37.786 | 55.550 | 78.351 | 86.534 | 97.787 |
| Total Income - EUR | - | 11.577 | 16.722 | 24.038 | 31.510 | 37.786 | 55.550 | 78.351 | 86.534 | 97.787 |
| Total Expenses - EUR | - | 560 | 645 | 1.006 | 620 | 219 | 868 | 277 | 8.916 | 15.831 |
| Gross Profit/Loss - EUR | - | 11.017 | 16.076 | 23.031 | 30.890 | 37.568 | 54.682 | 78.074 | 77.618 | 81.956 |
| Net Profit/Loss - EUR | - | 10.670 | 15.575 | 22.310 | 29.945 | 36.519 | 53.016 | 75.724 | 76.752 | 79.462 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Cabinet Neurologie Dr. Botezat Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 80 | 43 | 2 | 0 | 1.835 | 1.121 | 1.125 | 0 | 1.101 |
| Current Assets | - | 10.763 | 15.726 | 22.567 | 30.279 | 44.117 | 52.455 | 125.456 | 79.250 | 80.415 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 0 | 0 | 20.838 | 0 | 0 | 54.791 | 46.911 | 53.181 |
| Cash | - | 10.763 | 15.726 | 22.567 | 9.441 | 44.117 | 52.455 | 70.665 | 32.339 | 27.234 |
| Shareholders Funds | - | 10.714 | 15.619 | 22.353 | 29.987 | 36.560 | 53.056 | 75.764 | 76.793 | 79.520 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 129 | 151 | 215 | 292 | 9.391 | 520 | 50.816 | 2.457 | 1.997 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Cabinet Neurologie Dr. Botezat Srl